Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NuMe Health Inc.

This article was originally published in Start Up

Executive Summary

NuMe Health Inc. aims to market mixtures of edible substances that will act as "prebiotics" to shift ratios of certain bacteria in the lower intestine. The start-up intends to educate consumers about how "managing the microbiome" with products that are not drugs can positively affect metabolic health. First up: a mixture NuMe expects will improve biomarkers associated with pre-diabetes.

You may also be interested in...



Fat To Water: Big Hopes For Microbiome Approaches To Obesity and Metabolic Disease

Finding the right microbial balance in the gut may be the way of the future for treatment of conditions like obesity and diabetes. That’s where some notable medical futurists are looking and where some early commercial clinical trials are underway. In addition to all the usual uncertainties about new ideas in therapeutics, this idea has an extra question mark: what will the regulatory model be?

Despite Breakthroughs, No Hurry To Venture Into The Microbiome

A few start-ups and their backers have begun to pursue therapeutics for diseases modulated by our commensal, or beneficial, microbial populations. But the science is too new, and the VC world too shaken, to spur a rush to invest.

Despite Breakthroughs, No Hurry To Venture Into The Microbiome

A few start-ups and their backers have begun to pursue therapeutics for diseases modulated by our commensal, or beneficial, microbial populations. But the science is too new, and the VC world too shaken, to spur a rush to invest.

Related Content

Related Companies

UsernamePublicRestriction

Register

SC092166

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel